Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Memantine (Ebixa), glutaminergic modulator].

J Sternon1, J C Bier

  • 1Hôpital Erasme et CUMG-ULB, Bruxelles.

Revue Medicale De Bruxelles
|May 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[An update on treatment of dementia and Alzheimer's diseases?]

Revue medicale de Bruxelles·2017
Same author

Traitement Des Infections Bronchopulmonaires Aigues Par Le Laurylsulfate De Tetracycline Intra-Musculaire.

Acta clinica Belgica·2016
Same author

[Dementia, end of life and euthanasia].

Revue medicale de Bruxelles·2015
Same author

The Addenbrooke's Cognitive Examination Revised is as effective as the original to detect dementia in a French-speaking population.

Dementia and geriatric cognitive disorders·2012
Same author

[Evaluation of our psycho-educative program by participating caregivers].

Revue medicale de Bruxelles·2010
Same author

Neuropsychiatric disorders revealing primary antiphospholipid syndrome in an elderly patient.

Neurology·2010

Memantine offers a new therapeutic approach for Alzheimer's disease (AD) by targeting glutamate neurotoxicity. Combining memantine with cholinesterase inhibitors shows improved cognitive function and daily living activities in AD patients.

Area of Science:

  • Neuroscience
  • Gerontology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is the leading cause of dementia, with incidence rising exponentially with age.
  • Current treatments like anti-cholinesterasic drugs offer modest symptomatic relief but do not alter disease progression.

Purpose of the Study:

  • To investigate the therapeutic potential of memantine, a novel agent targeting glutamate excitotoxicity in AD.
  • To evaluate the efficacy of memantine, alone and in combination with donepezil, in patients with moderate to severe AD.

Main Methods:

  • Clinical evaluation of memantine (20 mg/day for 28 weeks) in patients with moderate to severe AD and mild to moderate vascular dementia.
  • Comparative analysis of memantine-donepezil combination versus placebo-donepezil in assessing cognitive functions and activities of daily living.

Related Experiment Videos

Main Results:

  • Memantine demonstrated clinical efficiency in patients with moderate to severe AD and vascular dementia.
  • The combination of memantine and donepezil showed significant improvements in cognitive functions and daily living activities compared to placebo-donepezil.

Conclusions:

  • Memantine represents a distinct therapeutic strategy for AD, addressing neurotoxic glutamate effects.
  • Combination therapy with memantine and donepezil shows promise for enhancing treatment outcomes in AD patients, warranting further investigation.